Ferring Pharmaceuticals Inc
General
Total Cases21
Active Cases2
Patents2
--
--
--
Ratings
Experience
Grade
Trend
DCT
L3
E
PTAB
--
--
--
CAFC
L3
E
Analytics
Cases
Litigated Patents
Ratings Trends
Recent Dockets
Entered | Case | Description |
|---|---|---|
| 11/12/24 | SO ORDERED re [130] Stipulation of Dismissal ***Civil Case Terminated. Signed by Judge Maryellen Noreika on 11/12/2024. (dlw) (Entered: 11/12/2024) | |
| 11/12/24 | STIPULATION of Dismissal by Ferring Pharmaceuticals Inc., Ferring International Center S.A., Ferring B.V., Polypeptide Laboratories A/S. (Bourke, Mary) (Entered: 11/12/2024) | |
| 10/07/24 | NOTICE OF SERVICE of Defendant Jiangsu Hansoh Pharmaceutical Group Co., Ltd.'s, (1) Reponses and Objections to Plaintiffs' Third Set of Requests for Production of Documents and Things (Nos. 41-80); and (2) Reponses and Objections to Plaintiffs' Third Set of Interrogatories (Nos. 14-21) filed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd..(Taylor, Daniel) (Entered: 10/07/2024) | |
| 09/13/24 | RESPONSE to Motion re [495] MOTION for Leave to File Reply in Support of Motion for Reconsideration [Opposition] filed by Finch Therapeutics Group, Inc., Finch Therapeutics Holdings, LLC., Finch Therapeutics, Inc., Regents of the University of Minnesota. (Farnan, Kelly) (Entered: 09/13/2024) | |
| 09/13/24 | Set Post Trial Briefing Schedule re [496] Motion Post-Trial Motion for Enhanced Damages, Ongoing Royalty, and Pre- and Post-Judgment Interest Pursuant to Order on D.I. 490 and [497] Renewed Motion for Judgment as a Matter of Law: Opening Briefs due 9/26/2024. Responsive Briefs due 10/30/2024. Reply Briefs due 11/21/2024. (*Briefing Schedule set by D.I. [490] ) (ceg) (Entered: 09/13/2024) | |
| 09/12/24 | MOTION for Judgment as a Matter of Law Ferring/Rebiotix's Renewed Motion for Judgment as a Matter of Law - filed by Ferring Pharmaceuticals Inc., Rebiotix Inc.. (Attachments: # [1] Text of Proposed Order)(Bourke, Mary) (Entered: 09/12/2024) | |
| 09/12/24 | Renewed MOTION for Judgment as a Matter of Law - filed by Ferring Pharmaceuticals Inc., Rebiotix Inc. (Attachments: # [1] Text of Proposed Order)(Bourke, Mary) Modified on 9/13/2024 (ceg). (Entered: 09/12/2024) | |
| 09/12/24 | MOTION Post-Trial Motion for Enhanced Damages, Ongoing Royalty, and Pre- and Post-Judgment Interest Pursuant to Order On D.I.490 re [490] , SO ORDERED,, Set Deadlines, - filed by Finch Therapeutics Group, Inc., Finch Therapeutics Holdings, LLC., Regents of the University of Minnesota. (Attachments: # [1] 7.1.1 Certification, # [2] Text of Proposed Order)(Farnan, Kelly) (Entered: 09/12/2024) | |
| 09/12/24 | Post-Trial MOTION for Enhanced Damages, Ongoing Royalty, and Pre- and Post-Judgment Interest Pursuant to Order on D.I.490 - filed by Finch Therapeutics Group, Inc., Finch Therapeutics Holdings, LLC., Regents of the University of Minnesota. (Attachments: # [1] 7.1.1 Certification, # [2] Text of Proposed Order) (Farnan, Kelly) Modified on 9/13/2024 (ceg). (Entered: 09/12/2024) | |
| 08/30/24 | MOTION for Leave to File Reply in Support of Motion for Reconsideration - filed by Ferring Pharmaceuticals Inc., Rebiotix Inc.. (Attachments: # [1] Exhibit Reply in Support of Motion for Reconsideration Regarding Summary Judgment of Patent Ineligibility Under 35 U.S.C. § 101, # [2] Text of Proposed Order)(Bourke, Mary) (Entered: 08/30/2024) |